Family History – GeneLit

Soluble interleukin-2 receptor as a predictive and prognostic marker for patients with familial breast cancer.
Gonda K, Horita S, Maejima Y, Takenoshita S, Shimomura K.
Sci Prog. 2021 Jul-Sep;104(3):368504211039590. doi: 10.1177/00368504211039590.

Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test.
Tung N, Desai N.
J Clin Oncol. 2021 Sep 7:JCO2101761. doi: 10.1200/JCO.21.01761. Epub ahead of print.

Original research:

Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.

Original research:

Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.

LitAlert ~~ GeneLit.com

Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms.
Elbracht M, Meyer R, Kricheldorf K, Gezer D, Thomas E, Betz B, Kurth I, Teichmann LL, Brümmendorf TH, Germing U, Isfort S, Koschmieder S.
Blood Adv. 2021 Sep 14;5(17):3373-3376. doi: 10.1182/bloodadvances.2021004811.

Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention.
Whitaker KD, Obeid E, Daly MB, Hall MJ.
JCO Precis Oncol. 2021;5:1387. doi: 10.1200/PO.21.00163. Epub 2021 Sep 1.

Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients.
Wieme G, Kral J, Rosseel T, Zemankova P, Parton B, Vocka M, Van Heetvelde M, Kleiblova P, Blaumeiser B, Soukupova J, van den Ende J, Nehasil P, Tejpar S, Borecka M, Gómez García EB, Blok MJ, Safarikova M, Kalousova M, Geboes K, De Putter R, Poppe B, De Leeneer K, Kleibl Z, Janatova M, Claes KBM.
Cancers (Basel). 2021 Sep 2;13(17):4430. doi: 10.3390/cancers13174430.

Synchronous detection of pancreatic adenocarcinoma and paraganglioma in a Whipple resection specimen.
Aaquist T, Dembic M, Thomassen M, de Stricker K, Bertelsen M, Christensen LG, Mortensen MB, Detlefsen S.
Pathol Res Pract. 2021 Aug 17;226:153590. doi: 10.1016/j.prp.2021.153590. Epub ahead of print.

Cancer predisposition and germline CTNNA1 variants.
Lobo S, Benusiglio PR, Coulet F, Boussemart L, Golmard L, Spier I, Hüneburg R, Aretz S, Colas C, Oliveira C.
Eur J Med Genet. 2021 Aug 20:104316. doi: 10.1016/j.ejmg.2021.104316. Epub ahead of print.

Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours.
Bellhouse S, Hawkes RE, Howell SJ, Gorman L, French DP.
Cancers (Basel). 2021 Aug 18;13(16):4150. doi: 10.3390/cancers13164150.

POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes.
Magrin L, Fanale D, Brando C, Fiorino A, Corsini LR, Sciacchitano R, Filorizzo C, Dimino A, Russo A, Bazan V.
Oncogene. 2021 Aug 6. doi: 10.1038/s41388-021-01984-2. Epub ahead of print.

Effective Surveillance of High Risk Women.
Lotz M, Ghebremichael M, Chervinsky K, Zorc T, Brenner C, Bousvaros G, Pories SE.
Clin Breast Cancer. 2021 Jul 27:S1526-8209(21)00200-7. doi: 10.1016/j.clbc.2021.07.014. Epub ahead of print.

Clinical and pathological features and risk factors for primary breast cancer patients.
Lei YY, Bai S, Chen QQ, Luo XJ, Li DM.
World J Clin Cases. 2021 Jul 6;9(19):5046-5053. doi: 10.12998/wjcc.v9.i19.5046.